Summary
The Rho family of GTPases regulates many aspects of cellular behavior through alterations to the actin cytoskeleton [1] [2] [3] [4] [5] [6] . The majority of the Rho family proteins function as molecular switches cycling between the active, GTP-bound and the inactive, GDP-bound conformations [1] [2] [3] [4] [5] [6] . Unlike typical Rho-family proteins, the Rnd subfamily members, including Rnd1, Rnd2, RhoE (also known as Rnd3), and RhoH, are GTPase deficient and are thus expected to be constitutively active [7] [8] [9] [10] . Here, we identify an unexpected role for RhoE/Rnd3 in the regulation of the p53-mediated stress response. We show that RhoE is a transcriptional p53 target gene and that genotoxic stress triggers actin depolymerization, resulting in actin-stressfiber disassembly through p53-dependent RhoE induction. Silencing of RhoE induction in response to genotoxic stress maintains stress fiber formation and strikingly increases apoptosis, implying an antagonistic role for RhoE in p53-dependent apoptosis. We found that RhoE inhibits ROCK I (Rho-associated kinase I) activity during genotoxic stress and thereby suppresses apoptosis. We demonstrate that the p53-mediated induction of RhoE in response to DNA damage favors cell survival partly through inhibition of ROCK I-mediated apoptosis. Thus, RhoE is anticipated to function by regulating ROCK I signaling to control the balance between cell survival and cell death in response to genotoxic stress.
Results and Discussion
We identified RhoE (also known as Rnd3) as a p53-responsive gene through a DNA-chip expression array that compared gene expression in the presence or absence of p53. To confirm this data, we looked for upregulation of RhoE mRNA and protein in the p53-inducible EJ cell line and through adenoviral (Ad) expression of p53 in p53-null Saos2 cells (Figure 1 ; also Figure S1 in the Supplemental Data available online). Because p53 is important in the DNA-damage response, the levels of RhoE mRNA and protein ( Figure 1B ; Figure S1 ) were studied in several p53-positive and -negative cell lines after treatment with various DNA-damaging agents: mitomycin C (MMC), etoposide (ETO), and camptothecin (CPT). RhoE was induced in response to p53 or DNA damage in cells containing wild-type p53 with kinetics similar to those of the p53-dependent gene, p21 (Figure 1A) . Inhibition of p53 activation in response to DNA damage, by means of p53 siRNA, abrogated RhoE induction ( Figure 1B ). We next investigated whether RhoE could be a direct p53 transcription target by mapping the transcriptional start site in a 5 0 RACE experiment and found three potential p53-binding sites (p53-BS) in the RhoE promoter; these sites matched the consensus p53 binding sequence by 80%-90% and contained the required conserved nucleotide sequence [11] (Figure 1C ). To test the p53 response of these sites on the RhoE promoter, we linked the promoter, containing the three potential binding sites at positions 2249, 2580, and 22220, to a luciferase reporter gene. Cotransfection of the construct with a wt-p53 expression plasmid into p53 null Saos2 cells increased luciferase activity significantly, whereas cotransfection with vector alone ( Figure 1C ) or mutant p53 (V143A) failed to do so (data not shown). We next generated point mutations at several consensus sequences of the three potential p53-BS in the RhoE promoter. A luciferase construct mutated at the 22220 position (designated M-1) significantly decreased luciferase activity in response to wtp53, whereas mutations in either the 2249 or 2580 sites had little effect on luciferase activity ( Figure 1C ). We transfected U2OS cells, containing wt-p53, with the luciferase constructs, then treated them with CPT for 24 hr to test the ability of endogenous p53 to activate the putative p53-BS in the RhoE promoter. These results confirm the data obtained in Saos2 cells, where transcriptional activity was only affected upon mutation of the 22200 p53-BS ( Figure 1C ). To determine whether p53 could bind to the RhoE promoter in vivo, we carried out a chromatin immunoprecipitation (ChIP) assay in Saos2 cells infected with Ad-p53 or Ad-GFP. The RhoE genomic fragment containing the 22200 p53-BS was specifically immunoprecipitated as a p53 protein-DNA complex with a p53 antibody but not with an HA antibody ( Figure 1D ; Figure S1 ). PCR amplification of a region containing a p53-binding site in the p21 promoter served as a positive control ( Figure 1D ). In order to examine whether endogenous p53 could bind to the RhoE promoter in vivo after DNA damage, we performed a ChIP assay in CPT-treated U2OS cells. The same genomic fragments were amplified from complexes immunoprecipitated with a p53-specific antibody but not with control IgG in DNA-damaged U2OS cells Figure 1 . p53-Dependent Induction of RhoE (A) RhoE mRNA is induced after tetracycline (tet) removal in EJ-p53 cells (tet-off). Total RNA was prepared from these samples, and northern blots were performed sequentially with 32 P-labeled probe against RhoE, p21, and 36B4 (loading control). Total RNA was prepared from other p53 +/+ and p53 2/2 cell lines after mitomycin C (MMC, 1 mg/ml) or etoposide (ETO, 25 mM) treatment at the indicated times. (B) U2OS and Saos2 cells were transfected with siRNA oligos targeting wt-p53 or luciferase control for 1 day, then treated with either 25 mM of ETO for 24 hr (U20S) or infected with adenovirus expressing p53 (Ad-p53) or Ad-GFP control (Saos2). Protein extracts were immunoblotted with RhoE, p21, p53, and b-actin antibodies. (C) The p53-binding site at -2200 is responsible for RhoE transcription. Luciferase assay reporter gene constructs containing the putative p53-recognition sequences within the RhoE promoter were co-transfected into Saos2 cells with either wt-p53 or control expression constructs. U2OS cells were also transfected with the reporter plasmids, then treated with 600 nM camptothecin (CPT) for 24 hr. The reporter plasmids used were the following: empty PGL3 vector, the full-length (FL) promoter, and six reporter constructs with p53-binding-site mutations (M1-M6); the p21 promoter was used as a control. The putative p53-recognition sequence within the RhoE promoter and the p53-consensus binding sequences (BS) are shown. Error bars represent the standard deviation from three independent experiments. (D) Chromatin immunoprecipitation (ChIP) assay of p53 DNA binding to the RhoE promoter. Saos2 cells were infected with Ad-p53 or Ad-GFP for 24 hr, then ChIP was performed with either a p53 antibody or an HA-tag antibody (negative control). U2OS cells were also used for ChIP analysis of endogenous p53 activity upon DNA damage by 24 hr treatment with 600 nM CPT. Amplification products were 235 bp (RhoE) and 417 bp (p21), respectively.
( Figure 1D ). Although the fragments were present in both DMSO-and CPT-treated U2OS cells, there was a significant increase in the amount of DNA amplified from the complexes of the DNA-damaged cells. ChIP assays performed with primers specific to either the 2249 or the 2580 p53-BS in the RhoE promoter demonstrated no significant binding (data not shown). These results indicate that RhoE is a transcriptional target of p53 and that the 22220 p53-BS plays a role in p53-mediated RhoE transcription.
To investigate whether RhoE induction in response to genotoxic stress contributes directly to p53-dependent stress responses, we used RhoE shRNA in the pBabe-U6-shRNA retroviral vector to knock down the induction of endogenous RhoE in response to DNA damage. Transfection of RhoE shRNA resulted in the suppression of endogenous RhoE induced by CPT treatment of U2OS cells, whereas control shRNA (scrambled) had no effect (Figure 2A ). To exclude off-target effects of shRNA, we used two independent RhoE shRNAs, both of which reduced RhoE expression (Figure 2A ). In subsequent experiments, the data presented incorporated the R1 RhoE shRNA and the results confirmed by transfection of R2.
RhoE is known to inhibit RhoA-mediated ROCK signaling and block actin-stress-fiber formation [7, 8, 10, 12, 13] . CPT treatment of U2OS cells induced a dramatic loss of actin stress fibers, as indicated by F-actin staining, whereas DMSO-treated cells maintained actin stress fibers ( Figure 2B ). Depletion of RhoE by shRNA in CPTtreated U2OS cells, as compared to cells expressing control shRNA, caused a reproducible recovery of actin stress fibers ( Figure 2B ), suggesting that RhoE induction was required for the DNA-damage-mediated loss of actin stress fibers. This recovery of actin stress fibers upon ablation of RhoE is consistent with overexpression studies showing that RhoE inhibits actin-stress-fiber formation [7, 8, 12] . Furthermore, suppression of RhoE in response to genotoxic insult resulted in a significant increase in apoptosis from approximately 20% to approximately 50% as measured by flow-cytometry analysis of cells stained with propidium iodide (PI) or by Annexin V/PI costaining ( Figure 2C ). To confirm the p53 dependence of RhoE's effect on apoptosis and to demonstrate that this result is not limited to U2OS cells, we repeated these experiments in normal dermal fibroblasts (IMR90), p53-null Saos2 cells, and p53 +/+ and p53 2/2 HCT116 cells ( Figures S2 and S3 ). p53 wild-type cells transiently transfected with shRhoE were able to enhance CPTinduced apoptosis, as measured by TUNEL and DNA fragmentation assays (Figures S2 and S3) . However, there was no noticeable change in the DNA-damage response upon RhoE knockdown in p53-null cells ( Figures  S2 and S3) . Although increased stress fiber formation was observed upon inhibition of RhoE and treatment with CPT ( Figure 2B ), at later time points we were able to see an increase in membrane blebbing, a hallmark of cellular apoptosis, in these cells compared to control cells ( Figure 2D ).
The concomitant increase in actin fibers and cell death in RhoE-depleted cells treated by DNA damage suggests a link between RhoE-mediated inhibition of actin-stress-fiber formation and ROCK I-mediated cell death. ROCK I is an emerging protein kinase that is responsible for membrane blebbing in apoptotic cells [14] [15] [16] [17] [18] [19] . Owing to the facts that RhoE interacts with ROCK I and that RhoE overexpression inhibits ROCK Iinduced myosin light chain (MLC) phosphorylation [12, 19] , we investigated whether RhoE induction by DNA damage inhibits ROCK I kinase activity. We determined the effect of RhoE depletion on endogenous ROCK I kinase activity by measuring the level of MYPT1 (regulatory subunit of MLC-phosphatase) phosphorylation. Although CPT-treated U2OS cells increased ROCK I activation more than 2-fold, depletion of RhoE in CPT-treated cells further increased ROCK I activity ( Figure 3A) . We also examined the effect of RhoE overexpression on ROCK I activity in CPT-treated 293ET cells containing dysfunctional p53. CPT treatment increased ROCK I activity in 293ET cells, but RhoE expression was not induced as a result of the lack of p53. Overexpression of RhoE was able to inhibit ROCK I activation ( Figure 3B ). These data suggest that p53 induction of RhoE antagonizes ROCK I-mediated cellular outcomes through a direct inhibition of ROCK I activity.
Given that RhoE expression inhibits ROCK I function and exerts a pro-survival effect in response to p53 and p53-dependent genotoxic stress, we investigated the possibility that ROCK I-mediated apoptosis is one of the apoptotic pathways activated in response to genotoxic stress and that RhoE modulates ROCK I-induced apoptosis. However, the role of ROCK I in apoptosis remains controversial [15, 17, 18, 20, 21] , with studies having been carried out in different cell types and with a variety of death-inducing agents. Therefore, we first needed to confirm that genotoxic stress induced ROCK I activation and cell death.
During apoptosis, the full-length ROCK I, at 160 kDa (wt-ROCK I), is cleaved by caspase-3 into two fragments, an active short form of ROCK I (s-ROCK I), at 130 kDa, and a 30 kDa cleaved fragment [14, 15, 22] . Cell lysates from CPT-or DMSO-treated U2OS cells were immunoblotted with a C-terminal-specific antibody that detects the full-length wt-ROCK I and the 30 kDa fragment (154C, Becton Dickinson) or an N-terminal-specific antibody (H-85, Santa Cruz) that recognizes wt-ROCK I and active s-ROCK I. ROCK I cleavage was detected in the CPT-treated cells but not in the DMSOtreated cells ( Figure 4A ). Transient transfection of U2OS cells were treated with either DMSO or Y-27632 (3 mM) for 24 hr and exposed to 600 nM CPT for the indicated time periods (24 and 48 hr). Cells were then assessed for apoptosis by TUNEL assay by both fluorescence microscopy and flow cytometry as described for (B and C).
ROCK I shRNA (RK1 siRNA sequence) resulted in a decrease of both forms of ROCK I in CPT-treated cells, whereas control shRNA had no effect on ROCK I levels ( Figure 4A ). To exclude potential off-target effects, we compared our designed ROCK I shRNA with that of the commercially available siRNA (Santa Cruz), and both of these reduced ROCK I expression (data not shown). In all subsequent experiments, our designed RK1 siRNA sequence was used. Whereas ROCK I shRNA had no effect on the induction of RhoE after DNA damage, RhoE shRNA treatment resulted in increased ROCK I activation ( Figure 4A ). Cleavage of PARP, an indicator of caspase-3 activation, was also reduced in ROCK I knockdown cells as compared to the control cells upon CPT treatment ( Figure 4A ), suggesting that ROCK I could affect caspase-3 activation through a feed-forward loop. A recent study also indicated that constitutively active ROCK I resulted in an increase in caspase 3 activity, and inhibiting ROCK I by shRNA suppressed further activation of caspase 3 upon ceramide treatment [23] .
To directly determine whether inhibition of ROCK I could influence genotoxic-stress-induced apoptosis, we used the TUNEL assay to analyze the level of apoptosis in CPT-treated U2OS cells in the presence of ROCK I or control shRNA. After the reduction of ROCK I expression, the percentage of cells undergoing apoptosis after CPT treatment was significantly decreased in comparison to that of control cells, whereas shRNA against RhoE resulted in an increase in cell death in response to CPT ( Figure 4B ). These data were confirmed with PI staining and a DNA fragmentation assay ( Figure S4 ). Similar results were obtained in HCT116 cells ( Figure 4C ) and mouse embryonic fibroblasts (MEF) (Figure S4 ), confirming that this result is not cell-type-dependent. We also examined whether the ROCK I inhibitor Y-27632 [24] could affect the DNA-damage-induced apoptotic response. Y-27632 prevented CPT-induced cell death to a level similar to that achieved by ROCK I shRNA transfection, as measured by a TUNEL assay ( Figure 4D ).
Because the 130 kDa s-ROCK I is known to be the active form of ROCK I generated in response to DNA damage [14, 15] , we investigated whether overexpression of s-ROCK I itself could result in apoptosis. U2OS cells were infected with adenoviruses (Ad) expressing s-ROCK I or wt-ROCK I. Overexpression of s-ROCK I caused a significant induction of cell death as measured by the number of TUNEL-positive cells ( Figure S5 ), but expression of wt-ROCK I failed to have any apoptotic effect. The ability of s-ROCK I to induce apoptosis was markedly abrogated in cells coinfected with Ads-ROCK I and Ad-RhoE ( Figure S5) . Consistent with previous studies [23] , these data demonstrate a direct correlation between the apoptotic response and ROCK I activation. Together, these data indicate that ROCK I may be an important mediator in apoptosis and that RhoE is a critical negative regulator of ROCK I activity, including ROCK I-mediated membrane blebbing and cell death.
Our results demonstrate that RhoE is a novel p53 transcriptional target gene that confers pro-survival effects in the p53-dependent response to genotoxic stress. Studies on RhoE indicate that it has two distinct functions, one in regulating the actin cytoskeleton and another in cell proliferation through inhibition of cellcycle progression [13] . Recently, it was shown that RhoE expression is significantly reduced in prostate cancer cells compared to normal prostate cells [25] , suggesting that RhoE has anti-proliferative effects [10] . However, RhoE expression is elevated in pancreatic tumors, colon cancer cells, and melanomas [26] [27] [28] , suggesting various roles for RhoE in different types of cancer. Our data point to RhoE's acting as a novel pro-survival factor whereupon induction of RhoE leads to the survival and propagation of cells that have sustained DNA damage. This is supported by the fact that cells with silenced RhoE show an increased propensity to undergo apoptosis in response to DNA damage. p53 pro-survival effectors such as RhoE, which are induced in damaged wt-p53-containing cells, play an important role in tissue damage and repair in response to DNA-damaging agents. Therefore, identifying the components of the novel p53/RhoE/ROCK I signaling pathway will provide an opportunity for therapeutic intervention by revealing novel drug-design targets that will potentially maximize the p53-dependent response and sensitize tumor cells to therapeutic drugs.
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